title: A phase II study of a daily x4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer.
abstract: BACKGROUND
  Because dose intensity may be important as a determinant response to vinorelbine, we explored the possibility of increasing the dose intensity of vinorelbine on a daily x4 schedule.
  
  
  METHODS
  Between February 1998 and March 1999, 31 patients with previously untreated advanced non-small cell lung cancer were enrolled. Vinorelbine 15 mg/m2 and cisplatin 20 mg/ m2 were administered intravenously daily for 4 days and repeated every 21 days.
  
  
  RESULTS
  A total 96 cycles were administered (median 3, range 1-6); 42% of vinorelbine and 39% of cisplatin injections were dose-reduced or delayed owing to toxicity. The actual dose intensity (DI) of vinorelbine was 17.7 mg/m2/week and that of cisplatin was 24 mg/m2/week. These figures represent 88 and 90% of the theoretical DI, respectively. The overall response rate was 40% (12/30, one CR). The main toxicity was myelosuppression: granulocytopenia WHO grade 3 and 4 in 24 patients (77%) and thrombocytopenia grade 3 in two patients (6%). The non-hematological toxicity was mild and tolerable. After a median follow-up of 7.5 months (range 3-21 months), the median progression-free survival and overall survival times were 5 months (95% CI, 3.8-6.2) and 8 months (95% CI, 4.5-11.5), respectively.
  
  
  CONCLUSIONS
  This regimen has a comparable therapeutic activity in patients with advanced lung cancers. However, despite supportive care there were excessive hematological toxicities. In view of increased toxicity and similar efficacy, this regimen is not indicated outside a clinical trial.
authors.affiliation: Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul.
authors.forename: J Y
authors.initials: JY
authors.lastname: Han
authors.forename: K W
authors.initials: KW
authors.lastname: Kim
authors.forename: J A
authors.initials: JA
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Kang
authors.forename: J Y
authors.initials: JY
authors.lastname: Jin
authors.forename: Y S
authors.initials: YS
authors.lastname: Hong
authors.forename: S Y
authors.initials: SY
authors.lastname: Park
authors.forename: J S
authors.initials: JS
authors.lastname: Song
authors.forename: J W
authors.initials: JW
authors.lastname: Park
authors.forename: H K
authors.initials: HK
authors.lastname: Kim
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: B G
authors.initials: BG
authors.lastname: Choi
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine